Condie Carmack

Peptidomimetics, synthetically modified peptides which have been engineered to eliminate certain undesirable features of native therapeutic peptides including short half-lives, immunogenicity, and delivery challenges, are a growing class of peptide-based therapeutics. Azapeptides (C to N substitution(s)), a type of peptidomimetic with several examples in clinical use, are known to exhibit increased resistance to endogenous proteases, … Read more

A recent study presented at the European Congress on Obesity reveals that individuals using weight loss drugs, including newer GLP-1 medications, tend to regain all lost weight within a year of discontinuing the medication. While these drugs effectively induce weight loss, maintaining a healthy lifestyle through diet and exercise remains crucial for long-term success.

The cost of prescription drugs in the U.S. has long outpaced that of peer nations, a dynamic driven by a combination of regulatory gaps, market forces, and lobbying pressure. Now, President Donald Trump is once again trying to tackle the issue—this time through an Executive Order that aims to pressure pharmaceutical companies to voluntarily lower … Read more

This systematic review and meta-analysis examines data for patients with diabetes and/or obesity from trials of GLP1-RA treatment to evaluate psychiatric, cognitive, and quality-of-life outcomes compared with placebo.

Weight-loss medications and bariatric surgery have both been found effective at helping people shed excess pounds — and now a new study explores their link to obesity-related cancer (ORC) risk. Obesity is a known risk factor for certain types of cancers, and has also been shown to impact cancer survival. Obesity-related cancers include multiple myeloma, … Read more